LogicBio Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update
LogicBio Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update - First patient for Phase 1/2 SUNRISE trial expected to be enrolled in early 2021 -Translational preclinical data for sAAVy platform shows substantial improvements over liver tropic capsids used in gene therapy programs to date -New Chief Scientific and Chief Financial Officers recently added to Executive Team News provided by Share this article Share this article LEXINGTON, Mass., March 15, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a clinical- stage gen...